Skip to main content

Multiplex Assays Market by Product, Technology & Application – 2021 | Marketsandmarkets

The report “Multiplex Assays Market Product (Consumable (Kits & Reagents, Panels), Type 9nucleic Acid-Based, Protein-Based), Technology (PCR, Planar Array), Application (R&D, Companion Diagnostics), End User (Hospital, Clinical Laboratory) – Global Forecast to 2021″, provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the multiplex assays market along with the estimates and forecasts of the revenue.

Browse 111 market data Tables and 59 Figures spread through 173 Pages and in-depth TOC on “Multiplex Assays Market Product (Consumable (Kits & Reagents, Panels), Type 9nucleic Acid-Based, Protein-Based), Technology (PCR, Planar Array), Application (R&D, Companion Diagnostics), End User (Hospital, Clinical Laboratory) – Global Forecast to 2021”
 
http://www.marketsandmarkets.com/Market-Reports/multiplex-assays-market-61593314.html
Early buyers will receive 10% customization on reports.

The multiplex assays market is projected to reach USD 3.76 Billion by 2021 from USD 2.66 Billion in 2016, growing at a CAGR of 7.2% during the forecast period (2016–2021).

The adoption of companion diagnostics for increasing safety & efficacy of therapies, need for effective analytical platforms in research to reduce operational costs, advantages of multiplexing over traditional assays are the major drivers for the multiplex assays market. Increasing validation of biomarkers in molecular and protein diagnostics are expected to further drive the growth of the multiplex assays market. However, high cost of multiplex assay instruments will restrain the growth of this market.

The multiplex assays market is broadly segmented into products & services, type, technology, applications, end users and regions. The products & services segment is further segmented into consumables, instruments, accessories, and software and services. The consumables subsegment is expected to account for the largest share of the products & services segment in 2016, owing to increasing demand for consumables.


On the basis of type, the multiplex assays market is categorized into nucleic acid-based assays and protein-based assays. Nucleic acid-based assays segment is further classified into planar nucleic acid assays and bead-based nucleic acid assays.. Protein-based assays segment is further categorized into planar protein assays and bead-based protein assays. The protein based assays segment is expected to be the fastest growing segment of the multiplex assays market in during the forecast period due to adoption of these assays in research purpose.

Factors such as need for effective analytical platforms in research to reduce operational costs are driving the growth of this segment.
The technology segment of the multiplex assays market is categorized into multiplex polymerase chain reaction, multiplex arrays, and other technologies. The multiplex arrays segment is further divided into planar arrays and bead-based arrays. The multiplex arrays segment is expected to account for the largest share of the multiplex assays market in 2016. The advantages of multiplexing over traditional assays, need for effective analytical platforms in research to reduce operational costs, and adoption of companion diagnostics for increasing safety & efficacy of therapy by multiplex assays are driving the growth of this segment.

The applications segment of the multiplex assays market is categorized into research & development, diseases & disorders, companion diagnostics, and other applications. The research & development segment is expected to account for the largest share of the multiplex assays market in 2016. Factors such as convenience in performing the assays and faster results offered by multiplex assays are driving the growth of this segment.

On the basis of end user, the multiplex assays market is segmented into academic and research institutes, hospitals, clinical laboratories, pharmaceutical and biotechnology companies, and other end users. The pharmaceutical and biotechnology companies segment is estimated to account for the largest share in 2016 due to increased adoption of multiplex assays in this segment.

Major players in the multiplex assays market include Luminex Corporation (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Illumina, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), and QIAGEN N.V. (Netherlands).


About MarketsandMarkets™:

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, “RT” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Rohan
MarketsandMarkets™
701 Pike Street,
Suite 2175, Seattle,
WA 98101, United States
1-888-600-6441
Email: sales@marketsandmarkets.com

Article Credit: Healthcare DC
Labels:

Comments

Post a Comment

Popular posts from this blog

Best Accounting Software to Kick-start the Business for Smaller Firms – Xero

  Xero Accounting Software is an online software mainly designed for the accounting needs of small business firms. The software can be operated from a PC, phone, tablet, or Mac to view the cash flows of the company in real-time. The software is for small business houses and hence it is simple to use yet smart so that the users can devote most of the time in other important areas of their business. USP of This Software: Xero accounting software offers accounting services to small business firms in a smarter way. Some of the USPs of the software the more than 800apps integrated into the software, secure encryption, support system better performance report generation, and others apart from the basic accounting services offered. Best Accounting Software for Medium-Sized Businesses@ https://blog.360quadrants.com/2020/best-accounting-software-for-medium-sized-businesses/ Xero Pricing Xero accounting software offers 30 days of free trial after which you can choose from any of the pri...
Post a Comment
Read more

Risk-based Monitoring Software Market | Key Factor in Clinical Trial | Market Growth Worth $511 million

  Growth in the risk based monitoring software market can primarily be attributed to factors such as the cost and time efficiency of RBM solutions, rising number of clinical trials, and increasing government funding and grants to support clinical trials. However, the high implementation cost of RBM solutions is expected to restrain the growth of this market during the forecast period. RBM Software Market Dynamics: Impact Analysis 1. Increased outsourcing of clinical trial processes to CROs 2. Cost and time efficiency of RBM solutions 3. Increasing government funding and grants to support clinical trials 4. Increased pharmaceutical R&D spending 5. Initiatives to boost digital health to propel market growth The risk-based monitoring (RBM) software market is expected to reach USD 511 million by 2025 from USD 273 million in 2020, at a CAGR of 13.3% Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=102112429 Software Component: The sof...
Post a Comment
Read more

Cell Sorting Market

The global  cell sorting market  is projected to reach USD 247.4 Million by 2021, at a CAGR of 7.0% in the forecast period (2016-2021). Factors such as technological advancements in cell sorters, rising funding and investments for development of technologically advanced cell sorters, and growing adoption of cell sorting techniques in research activities are driving the growth of global Market. The market is further driven by factors such as the growing prevalence of HIV/AIDS and cancer, expanding pharmaceutical and biotechnology industries, and launch of specific reagents for specific applications. However, factors such as the high cost of instruments and lack of awareness & technical knowledge regarding the use of cell sorters are hampering the growth of market. Geographically, the market is segmented into North America, Europe, Asia-Pacific, and RoW. Among the four geographic regions, North America is estimated to command the largest share of the market in 2016, foll...
Post a Comment
Read more